Author

Paolo Armanetti

Istituto di Fisiologia ClinicaORCID 0000-0002-8516-536XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:clustering· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:imaging· 1

Frequent Co-Authors

Elena LevantiniiD· 2 shared Emilia BramantiiD· 2 shared Eva Cabrera San MillániD· 2 shared Giorgia MaroniiD· 2 shared Raffaella MercatelliiD· 2 shared Alessandro ZegaiD· 1 shared Alice ChiodiiD· 1 shared Arianna ConsiglioiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Elena LevantiniORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Longitudinal per-lesion in vivo imaging reveals allele-dependent resistance evolution in EGFR-mutant lung cancer

Eva Cabrera San Millán, D M Panetta, Paolo Armanetti, Mauro Quaglierini, Alessandro Zega, Raffaella Mercatelli, Emilia Bramanti, L Menichetti, Giorgia Maroni, Elena Levantini

This study uses longitudinal in vivo imaging to show how different EGFR mutations affect resistance evolution in lung cancer lesions under therapy.

bioRxiv · Apr 18, 2026 · PreprintCancer Biology

The two sides of resistance: aggressiveness and mitotic instability as the Achilles heel of Osimertinib-resistant NSCLC

Paolo Armanetti, Eva Cabrera San Millán, Raffaella Mercatelli, Chiara Cavallini, Alice Chiodi, Ettore Mosca, Arianna Consiglio, Nicola Losito, Luca Menichetti, Emilia Bramanti, Azhar Ali, Elena Levantini, Giorgia Maroni

This study identifies BMI1 as a driver of Osimertinib resistance in NSCLC by promoting mitotic instability and aggressiveness, and shows that targeting BMI1 with Unesbulin can suppress tumor growth.

bioRxiv · Sep 25, 2025 · PreprintCancer Biology